Lv5
856 积分 2024-01-26 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Multiplex Immunohistochemistry Analysis of Melanoma Tumor-Infiltrating Lymphocytes
3个月前
已关闭
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
4个月前
已完结
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
5个月前
已完结
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
5个月前
已完结
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
5个月前
已完结
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
5个月前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
5个月前
已完结
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
6个月前
已完结
皖公网安备34019202002308
